Comparative evaluation of ELPylated virus-like particle vaccine with two commercial PCV2 vaccines by experimental challenge. Issue 23 (13th May 2020)

• Record Type: Journal Article
• Authors: Li, Yangyang; Lin, Yan; Xin, Gang; Zhou, Xiaohui; Lu, Huipeng; Zhang, Xinyu; Xia, Xiaoli; Sun, Huaichang
• Is Part Of: Vaccine. Volume 38:Issue 23(2020)
• Page Start: 3952
• Page End: 3959
• Publication Date: 2020-05-13
• Subjects: PCV2 -- ELPylated VLP vaccine -- Vaccine efficacy -- Comparison; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2020.03.060
• Languages: English
• ISSNs: 0264-410X

Abstract

Highlights: We compare ELP-VLP vaccine efficacy with two commercial PCV2 vaccines. We demonstrate that ELP-VLP induces stronger VN antibody and IFN-γ responses. We show that ELP-VLP is more effective against PCV2 infection. Abstract: Porcine circovirus type 2 (PCV2) is an economically important swine pathogen and vaccination is the primary tool for the disease control. Previously, we developed a more cost-effective PCV2 virus-like particle (VLP) vaccine by using ELPylation technology. In the present study, we compared the ELPylated VLP (ELP-VLP) PCV2 vaccine efficacy with commercial inactivated Yuanlijia vaccine and VLP-based Circoflex vaccine by experimental challenge. After one dose of vaccination with the three different vaccines, ELP-VLP vaccine group showed significantly ( p < 0.05) stronger virus neutralizing antibody and interferon-γ responses than the two commercial vaccine groups. All vaccinated pigs showed significant ( p < 0.05) improvement in average daily weight gain (ADWG) before challenge. After challenge with PCV2, however, only ELP-VLP-vaccinated pigs showed significant ( p < 0.05) improvement in ADWG. All vaccinated pigs showed significant ( p < 0.05) reductions in PCV2 loads in the blood, nasal secretion and lymph nodes, ELP-VLP-vaccinated pigs in particular. In addition, vaccination with ELP-VLP vaccine provided stronger protection against pulmonary and lymphoid pathologies than that with the two commercial vaccines. Therefore, ELP-VLP vaccine is more effective to control PCV2 infection than the two commercial vaccines based on clinical, immunological, virological and pathological evaluations.